These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 19731999)
1. Value of new biomarkers for safety testing in drug development. Hewitt P; Herget T Expert Rev Mol Diagn; 2009 Sep; 9(6):531-6. PubMed ID: 19731999 [No Abstract] [Full Text] [Related]
2. From biomarker strategies to biomarker activities and back. van Gool AJ; Henry B; Sprengers ED Drug Discov Today; 2010 Feb; 15(3-4):121-6. PubMed ID: 19931413 [TBL] [Abstract][Full Text] [Related]
3. Applications of 'decisionable' biomarkers in cardiovascular drug development. Krishna R; Wagner JA Biomark Med; 2010 Dec; 4(6):815-27. PubMed ID: 21133701 [TBL] [Abstract][Full Text] [Related]
5. Beyond biomarkers: an opportunity to address the 'pharmacodynamic gap' in pediatric drug development. Kearns GL Biomark Med; 2010 Dec; 4(6):783-6. PubMed ID: 21133695 [No Abstract] [Full Text] [Related]
6. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors. Ichimaru K; Toyoshima S; Uyama Y Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436 [No Abstract] [Full Text] [Related]
7. Noninvasive structural, functional, and molecular imaging in drug development. Rudin M Curr Opin Chem Biol; 2009 Jun; 13(3):360-71. PubMed ID: 19447067 [TBL] [Abstract][Full Text] [Related]
10. The new revolution in toxicology: the good, the bad, and the ugly. Davis M; Boekelheide K; Boverhof DR; Eichenbaum G; Hartung T; Holsapple MP; Jones TW; Richard AM; Watkins PB Ann N Y Acad Sci; 2013 Mar; 1278():11-24. PubMed ID: 23488558 [TBL] [Abstract][Full Text] [Related]
11. Chutes and ladders on the critical path:comparative effectiveness, product value, and the use of biomarkers in drug development. Woodcock J Clin Pharmacol Ther; 2009 Jul; 86(1):12-4. PubMed ID: 19536116 [No Abstract] [Full Text] [Related]
12. Traditional medicine-inspired approaches to drug discovery: can Ayurveda show the way forward? Patwardhan B; Mashelkar RA Drug Discov Today; 2009 Aug; 14(15-16):804-11. PubMed ID: 19477288 [TBL] [Abstract][Full Text] [Related]
13. [Toxicogenomics Project and drug safety evaluation.]. Urushidani T Nihon Yakurigaku Zasshi; 2010 Jul; 136(1):46-9. PubMed ID: 20628214 [No Abstract] [Full Text] [Related]
14. A network-heuristic approach to improve the impact of genomic data on drug discovery. Trister AD; Huang ES Clin Pharmacol Ther; 2013 Apr; 93(4):295-7. PubMed ID: 23511782 [TBL] [Abstract][Full Text] [Related]
15. A tiered approach to address regulatory drug metabolite-related issues in drug development. Ma S; Chowdhury SK Bioanalysis; 2014 Mar; 6(5):587-90. PubMed ID: 24620798 [No Abstract] [Full Text] [Related]
16. QT as a safety biomarker in drug development. Whellan DJ; Green CL; Piccini JP; Krucoff MW Clin Pharmacol Ther; 2009 Jul; 86(1):101-4. PubMed ID: 19474784 [TBL] [Abstract][Full Text] [Related]
17. Flow cytometry-based biomarkers in translational medicine and drug development. Litwin V; O'Gorman MR J Immunol Methods; 2011 Jan; 363(2):101-2. PubMed ID: 20888828 [No Abstract] [Full Text] [Related]
18. A reflection on fit-for-purpose metabolite investigation at different stages of drug development. Leclercq L Bioanalysis; 2014 Mar; 6(5):591-4. PubMed ID: 24620799 [No Abstract] [Full Text] [Related]
19. In vivo model of pseudomyxoma peritonei for novel candidate drug discovery. Chua TC; Akther J; Yao P; Morris DL Anticancer Res; 2009 Oct; 29(10):4051-5. PubMed ID: 19846950 [TBL] [Abstract][Full Text] [Related]